drug · small molecule

VOQUEZNA

updated 3mo ago

by $PHAT Phathom Pharmaceuticals, Inc.🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 8

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 14 approved and 2 investigational indications.

targets

Potassium-transporting ATPase

all catalysts(0)

nothing on the calendar yet

Trials studying VOQUEZNA

phase1Bioequivalence Study to Compare Vonoprazan 20 mg Film Coated Tablets Versus Voquezna® 20 mg (Vonoprazan) Tabletscompletedn=28

News(0)

no news has mentioned this drug yet

brand

VOQUEZNA

trade names

Voquezna

generic

VONOPRAZAN FUMARATE

MOA

12.1 Mechanism of Action Vonoprazan suppresses basal and stimulated gastric acid secretion at the secretory surface of the gastric parietal cell through inhibition of the H + , K + -ATPase enzyme system in a potassium competitive manner. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, vonoprazan has been characterized as a type of gastric proton-pump inhibitor, in that it blocks the final step of acid production. Vonoprazan does not require activation by acid. Vonoprazan may selectively concentrate in the parietal cells in both the resting and stimulated states. Vonoprazan binds to the active proton pumps in a noncovalent and reversible manner. Amoxicillin is an antibacterial drug. Clarithromycin is a macrolide antimicrobial drug [see Microbiology (12.4) ]. Acid suppression enhances the replication of H. pylori bacteria and the stability and effectiveness of antimicrobials in the treatment of H. pylori infection.

indication

1 INDICATIONS AND USAGE VOQUEZNA TRIPLE PAK, is a co-packaged product containing vonoprazan, a potassium-competitive acid blocker (PCAB), amoxicillin, a penicillin class antibacterial, and clarithromycin, a macrolide antimicrobial, indicated for the treatment of Helicobacter pylori (H. pylori) infection in adults. ( 1.1 ) VOQUEZNA DUAL PAK, is a co-packaged product containing vonoprazan, a PCAB, and amoxicillin, a penicillin class antibacterial, indicated for the treatment of H. pylori infection in adults. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of VOQUEZNA TRIPLE PAK, VOQUEZNA DUAL PAK and other antibacterial drugs, VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) 1.1 Helicobacter pylori Infection VOQUEZNA TRIPLE PAK or VOQUEZNA DUAL PAK are indicated for the treatment of Helicobacter pylori ( H. pylori ) infection in adults [see Clinical Studies (14) ]. 1.2 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of VOQUEZNA TRIPLE PAK, VOQUEZNA DUAL PAK and other antibacterial drugs, VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 17m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · small molecule

save

VOQUEZNA

updated 3mo ago

by $PHAT Phathom Pharmaceuticals, Inc.🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 8

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 14 approved and 2 investigational indications.

targets

Potassium-transporting ATPase

all catalysts(0)

nothing on the calendar yet

Trials studying VOQUEZNA

phase1Bioequivalence Study to Compare Vonoprazan 20 mg Film Coated Tablets Versus Voquezna® 20 mg (Vonoprazan) Tabletscompletedn=28

News(0)

no news has mentioned this drug yet

brand

VOQUEZNA

trade names

Voquezna

generic

VONOPRAZAN FUMARATE

MOA

indication

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 17m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

VOQUEZNA

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying VOQUEZNA

News(0)

Report a data issue

comments(0)

VOQUEZNA

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying VOQUEZNA

News(0)

Report a data issue

comments(0)